Theodrenaline

DB12927InvestigationalSmall molecule

Theodrenaline is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

Mechanism: Pharmacologically active on Beta-1 adrenergic receptor and Cyclic nucleotide phosphodiesterase
Curator reviewed
Formula / weight: C₁₇H₂₁N₅O₅ · 375.385 g/mol (avg)

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyWMCMJIGLYZDKRN-UHFFFAOYSA-NSMILESCN1C2=C(N(CCNCC(O)C3=CC(O)=C(O)C=C3)C=N2)C(=O)N(C)C1=O

Targets

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,126Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 23 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Theodrenaline, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.